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Health technology assessment (HTA) is increasingly informed by nonrandomized studies, but there is
limited guidance from HTA bodies on expectations around evidence quality and study conduct. We
developed recommendations to support the appropriate use of such evidence based on a pragmatic
literature review and a workshop involving 16 experts from eight countries as part of the EU’s Horizon-
2020 IMPACT-HTA program (work package six). To ensure HTA processes remain rigorous and robust, HTA
bodies should demand clear, extensive and structured reporting of nonrandomized studies, including
an in-depth assessment of the risk of bias. In recognition of the additional uncertainty imparted by
nonrandomized designs in estimates of treatment effects, HTA bodies should strengthen early scientific
advice and engage in collaborative efforts to improve use of real-world data.
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Most health technology assessment (HTA) bodies profess a strong preference for evidence on treatment effects from
randomized controlled trials (RCTs) over nonrandomized studies due to a lower risk of bias by design [1]. However,
with an increasing number of medicines receiving regulatory approval based on nonrandomized evidence, HTA
bodies are being tasked with issuing recommendations on new technologies in the absence of RCTs or with limited
RCT data [2–5]. For other health technologies like medical devices, nonrandomized studies already provide the
predominant source of evidence [3]. Nonrandomized studies are defined broadly here to include all study designs
without randomization, including nonrandomized clinical trials, observational studies and trials with external
controls [4].
The quality of nonrandomized studies so far accepted by HTA bodies for decision making has been variable [2–5,5]
and there is a widely acknowledged lack of transparency in research governance throughout the evidence generation
process [6,7]. In this paper we present recommendations aimed both at those generating evidence and HTA bodies
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to ensure that where nonrandomized studies are of potential value, they are conducted in transparent and robust
ways to maximize their usefulness for decision making.
The use of nonrandomized evidence to estimate treatment effects
RCTs are widely recognized as the gold standard for estimating treatment efficacy because of the ability of
randomization in ensuring any differences in baseline characteristics between groups are due to chance, blinding
(where applied) in preventing knowledge of treatment allocation from influencing behaviors and standardized
protocols in ensuring consistent data collection [8]. RCTs are not; however, immune to bias. More than half of the
pivotal studies in oncology submitted to the EMA between 2014 and 2016 were judged to be at high risk of bias
for their primary end point [9]. Further, many well-conducted RCTs have limitations with regard to establishing
comparative effectiveness for HTA including comparisons to treatments (or placebo) other than usual care, selected
patient populations, insufficient follow-up, treatment protocols that deviate from usual care and the use of surrogate
outcomes which may not predict the outcome(s) of ultimate interest. Against this background, there is at least the
potential that well-conducted nonrandomized studies based on high quality and relevant (e.g., inclusion of patient
relevant outcomes) data could improve decision making.
In addition, RCTs may be considered unethical (e.g., last line cancer therapies) or infeasible (e.g., due to small
numbers of eligible patients) [10]. There has been an increase in the use of expedited access programs by regulatory
authorities to facilitate faster patient access to innovative treatments, particularly in oncology and rare diseases,
where single-arm trials are common [11]. Following approval through expedited regulatory pathways, HTA bodies
are required to make initial reimbursement and/or pricing decisions based on this limited evidence [12–15]. When
substantial uncertainties exist about the clinical evidence for a highly promising treatment, and data collection to
resolve the uncertainties is feasible, a conditional reimbursement decision may be given, requiring an outcomes-
based managed entry agreement to collect data post reimbursement to resolve the uncertainties, commonly in the
form of a nonrandomized study [13].
Nonrandomized studies are typically at a higher risk of bias than RCTs because patients are not randomly
allocated to treatment and treatment allocation is known; instead, physicians decide on a patient’s treatment based
on their expectation of the benefit–risk profile of different treatments for that patient and their preferences [14].
Bias may also arise from poor data quality including errors in data entry, measurement error, misclassification of
exposures and outcomes, missing data or from poor analytical choices, coding errors or selective reporting and/or
publication of results [15].
There is mixed evidence on the internal validity of nonrandomized studies. A 2017 review of 14 meta-
epidemiological studies reported that seven found no systematic differences between RCTs and nonrandomized
studies, five found estimates from nonrandomized studies to systematically exceed those from RCTs and the remain-
ing two were inconclusive [16]. A recent meta-epidemiological study conducted by IMPACT-HTA work package
six consortium found no evidence of a systematic difference in treatment effects for pharmaceutical interventions
but substantial variation in these differences for specific clinical questions. Similar results were observed among
the first ten trial emulations from the RCT-DUPLICATE project in which RCTs were replicated in US claims
databases [17]. There is stronger evidence that nonrandomized studies relying on external controls, such as single-arm
trials, are associated with greater bias on average than other types of nonrandomized studies [16].
Despite the increasing availability of observational data and advances in analytical methods, RCTs remain the
main source of evidence on treatment effects for medicines [18]. Where nonrandomized studies are used, they are
usually based on single-arm trials and have predominantly been in oncology, infectious diseases and for rare disease
treatments. The proportion of submissions using nonrandomized evidence is increasing: more than half of all
NICE’s medicines appraisals between 2010 and 2016 using nonrandomized data on clinical effectiveness were in
2015–16 alone [19]. For other types of health technologies like medical devices, there has long been a greater reliance
on nonrandomized studies to estimate treatment effects as regulatory requirements do not generally demand RCTs
and RCTs may be difficult to perform [3].
Despite the pervasive risk of bias from confounding in nonrandomized studies, many HTA bodies and regulators
have accepted submissions using no or only simple methods of adjustment [5,19]. Anderson et al. [19] found that of
the 22 medicines appraised by NICE using nonrandomized data between 2010 and 2016, only five used a regression
approach to adjust for confounding while two-thirds used naive unadjusted indirect comparison to aggregate data.
A persistent challenge is that for clinical questions where RCTs cannot be performed due to small patient numbers,
there is also likely to be limited observational data, inhibiting the extent of adjustment possible in analyses.
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Recommendations for the use of nonrandomized studies in comparative effectiveness
estimation
Materials & methods
The work consisted of two key activities. First, we undertook two pragmatic reviews. The first focused on empirical
assessments of the internal validity of treatment effect estimates from nonrandomized studies. We reviewed such
studies that were included in a Cochrane umbrella review published in 2014 [20] and another, pragmatic review
published in 2017 [21]. To capture more recently published studies, we also replicated the search from the Cochrane
review for one database (MEDLINE via PubMed) up until September 2018. Our second review focused on
best-practice recommendations for the generation of evidence on the effects of new technologies from reports and
guidance from HTA bodies and societies, payers, regulators and real-world evidence research consortia including
CADTH, European Network for Health Technology Assessment (EUnetHTA), Haute Autorite de Sante (HAS),
Health Information and Quality Authority (HIQA), Institute for Clinical and Economic Review (ICER), Rijksin-
stituut voor Ziekte en Invaliditeitsverzekering (INAMI-RIZIV), Institut fur Qualitat und Wirtschaftlichkeit im
Gesundheitswesen (IQWiG), National Institute for Health and Care Excellence (NICE), Pharmaceutical Benefits
Advisory Committee (PBAC), Scottish Medicines Consortium (SMC), Tandvards-och lakemedelsformansverket
(TLV), Zorginstituut Nederlands (ZIN), US FDA, EMA, Duke Margolis, ENCePP, GetReal, HTAi, ISPE, ISPOR,
RWE4Decisions and REALISE. We identified additional papers and reports through the reference lists of identified
sources and through discussion with experts. We also conducted ad-hoc literature reviews to identify additional
academic papers on specific topics. The review was restricted to English language reports, which represents a
limitation of this work.
We drafted an initial list of key recommendations based on our literature review. These were revised based on
consultation with European HTA bodies and regulators. We held an online workshop in June 2020 involving 16
participants (see acknowledgements) from eight countries across Europe (the UK, the Netherlands, Spain, Germany,
Norway, Sweden, Austria and Italy). Initial recommendations were shared with all participants prior to the meeting
and the revised set were sent for written comment after the meeting. Written comments were incorporated to arrive
at the list of considerations presented in this paper.
Recommendations
Conduct of nonrandomized studies
Planning & design
Justify the need for a nonrandomized study & demonstrate that the research question is amenable to being answered using
nonrandomized data.
The need for a nonrandomized study should be justified and research questions should be clearly defined using
established frameworks [22,23]. Where observational data are considered for use as part of a nonrandomized study,
it is important to ascertain that: the question is amenable to being answered using observational data [24], and that
one or more data sources containing sufficient information of high quality and relevant to the decision context are
available and accessible [25]. Datasets should be identified through a systematic, transparent and reproducible process
to ensure the most appropriate data are used [26,27]. This avoids the selection of datasets based on convenience or
the knowledge or expectation of deriving particular results.
Plan studies prospectively and engage in early scientific advice procedures
Nonrandomized studies should be planned prospectively to negate the possibility of selective methodology and
results [7]. Study sponsors should take advantage of scientific consultation processes where available to help guide
evidence generation throughout a product’s lifecycle. Scientific advice provides an essential function in allowing HTA
bodies and regulators to work with stakeholders to ensure that plans for evidence generation deliver information
that supports and improves decision making in both premarket and postmarket settings [28,29].
Analysis
Understand potential risks of bias & address using appropriate analytical strategies
Bias may arise in nonrandomized studies for numerous reasons including patient selection, confounding or data
limitations [30]. The potential mechanisms of bias for any application should be clearly articulated and the analysis
plan designed to elucidate and minimize potential bias. Analysts can seek to address bias through the application
of statistical methods or study design. An increasingly common approach is to try to replicate RCT designs – the
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‘target trial’ approach [31]. This involves numerous design principles, but key among these are restricting cohorts
to new users, using active comparators (as opposed to nonusers), adjusting based on pretreatment confounders
(e.g., using propensity score matching), performing or utilizing outcome validation studies and prespecifying
sensitivity analyses. In practice, this can be difficult to achieve given the limitations of many observational datasets.
In addition, for novel therapies and for certain conditions, it may not be possible to identify appropriate active
comparators, while early users of a technology may differ from the target population [32]. Where using external
control arms, high-quality individual patient level data (rather than aggregate data) from contemporaneous (or where
necessary, historical) controls should be used for adjustment as it provides greater scope to control for differences
between patients [33]. Regardless of study design, potential confounders should typically be defined prior to study
conduct and based on the scientific literature and through engagement with clinical experts [34].
Perform extensive sensitivity analyses
Nonrandomized studies involve many decisions and assumptions including in data curation and analysis, each of
which, alone or in combination, could have substantial effects on the resulting estimates. It is therefore, essential that
extensive sensitivity analyses are undertaken to understand the robustness of the results to data curation, design and
analysis decisions and characterize the uncertainty in the treatment effect [35,36]. This could be complemented by
quantitative bias analysis, which includes techniques such as negative controls, the use of external information and
threshold analysis, in other words, identifying the extent of bias sufficient to change decisions [37]. Finally, where
possible there should be an attempt to replicate findings in one or more datasets [38].
Reporting
Register protocols before study conduct
Detailed study protocols including statistical analysis plans should be registered before the beginning of the study
on publicly accessible platforms using structured reporting templates, and amendments to the protocols should be
clearly reported and justified [7]. This would improve study transparency and allay concerns about selective analyses
and selective reporting as well as publication bias, which are major impediments to the acceptability and wider use
of nonrandomized evidence [39].
Report data, methods & results transparently
It is essential that all information pertaining to evidence quality is clearly and comprehensively reported. This
includes descriptions of data fitness-for-purpose, encompassing data quality and relevance, reporting of study
conduct including data curation, analysis and results. Traditional reporting checklists play an important role in the
transparent reporting of nonrandomized study methods and results by ensuring that key information is reported [40].
While they should be used in evidence submissions, they are not generally sufficient to support reproduction and
are not an indicator of quality. Novel approaches to transparent reporting provide structured templates to articulate
study design and analysis and the assumptions underlying them [41]. Ideally reviewers of submitted evidence,
including HTA bodies or independent review groups, would also have access to the data and analytical code to
ensure the replicability of the submitted results and assess the impact of alternative analytical decisions or data
on the resulting estimate(s). However, there remain substantial governance, technical and practical challenges to
sharing data, including a lack of in-house expertise in many HTA agencies [42]. Validated analytical platforms can
complement preregistration in promoting transparency by ensuring a correct ordering and comprehensive account
of study conduct, while reducing the risk of analytical or coding errors [35].
Describe potential biases & report the overall risk of bias
Study sponsors should clearly articulate potential causes of bias and their impact on estimated treatment effects.
The overall risk of bias should also be formally assessed using well-validated tools [43]. For nonrandomized studies,
the ROBINS-I tool is recommended by the European network for HTA (EUnetHTA) and assesses the risk of
bias by specifying the research question as a target trial and considering risks from seven domains of bias namely
bias due to confounding, in selection of participants into the study, in classification of interventions, due to
deviations from intended interventions, due to missing data, in measurement of outcomes and in the selection of
the reported result [44]. Other sources of bias beyond those covered within existing quality assurance tools should
also be documented [43]. Ideally, quantitative estimates of bias would also be presented [37].
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Convey & ideally quantify the uncertainty
Uncertainty is pervasive in HTA, particularly where estimates of effects and costs are required over the long-
term. Although several meta-epidemiological studies, as well as trial replication studies, have found no evidence
of systematic differences in treatment effect estimates between RCTs and nonrandomized studies, there was
great variation in estimates across clinical questions. Unless a decision maker is able to identify when differences
are likely to be present and the direction and magnitude of any differences, then they must acknowledge the
sizeable additional uncertainty involved in the use of nonrandomized evidence which will not be fully captured by
the statistical uncertainty in the estimated effectiveness parameter [45]. This uncertainty should be appropriately
conveyed and ideally quantified, in evidence submissions.
Further considerations for HTA bodies
Strengthening systems
Strengthen & standardize scientific advice procedures
Scientific advice provides an opportunity to enhance quality and relevance of evidence submitted to HTA bodies,
but they are often limited to discussion of RCTs. HTA bodies should consider extending their use to discuss any
nonrandomized evidence that will be important in the determination of value and ensure that experts providing
the advice have expertise in the evaluation of such studies. Furthermore, international scientific advice processes are
to be encouraged with collaboration over best practice guidelines that can be referred to in relation to the design
and conduct of nonrandomized studies, such as those presented in this paper.
Strengthen conditional reimbursement processes to ensure generation of further informative evidence after initial reimbursement
decisions
Uncertainty poses the risk that incorrect decisions will be made that are detrimental to population health. Managed
entry agreements of various forms have the potential to ameliorate the impact of uncertainty and are widely
used throughout Europe [28,46]. A perceived lack of transparency around such schemes means there has been an
incomplete understanding of their strengths and limitations. Some outcomes-based managed entry agreements that
have sought to collect data for later reappraisal have been compromised by several procedural and methodological
limitations with poor quality studies commissioned and limited impact on decision making [47]. These experiences
underscore the importance of having high-quality evidence available at the time of the initial approval. When such
outcomes-based managed entry agreements are used, it is imperative that clear responsibilities for data collection
and analysis are defined and that appropriate enforcement mechanisms are available to HTA bodies to ensure timely
delivery of high-quality evidence. Data collection and analysis should follow best practice guidance and be reported
and published transparently. Further guidance is provided in work package ten of the IMPACT HTA project [48].
Invest in & develop staff skills in the design, analysis & interpretation of nonrandomized studies
As an increasing number of HTA submissions are made on the basis of nonrandomized data and as HTA bodies
respond by commissioning and designing studies and perhaps even analyzing data, it is imperative that their staff
and decision making committees possess the requisite skills to conduct this work [39]. This is likely to require both
training and recruitment. International collaboration with experts is also essential to share expertise and develop
methods specifically for HTA.
Issuing & enforcing best practice guidance
To ensure the generation of high-quality evidence suitable for decision making, HTA bodies should issue clear guid-
ance on data quality standards and best practice methods for the design, conduct and reporting of nonrandomized
studies and ensure that these are followed. There are several ongoing initiatives to establish frameworks for the use
of real-world evidence in decision making including by the FDA, EMA and NICE [13,49,50]. It is essential that these
tools are built in a collaborative fashion to streamline evidence generation and ensure adoption. They should aspire
to be simple to apply and interpret so as to enhance transparency and reduce the burden on sponsors and decision
makers. This would also benefit smaller HTA bodies and payers who have fewer resources to conduct detailed
assessments themselves. This work could also include clear guidance as to when nonrandomized studies will be
considered and where they are expected. Because this is an evolving field, it is important that these frameworks are
regularly revised.
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Supporting future research & initiatives
Support access to high-quality data
HTA bodies should support international efforts to set data standards; thereby, improving the quality and inter-
operability of data. They should also support initiatives to improve data linkage and access while ensuring data
protection is maintained which could include the exploration of trusted research environments, federated data
networks and the development of high-quality synthetic datasets.
Support methodological and empirical research
HTA bodies should further support research efforts to advance methods for causal estimation and evidence synthesis
and empirical investigations into the performance of different nonrandomized study designs across different use
cases to better understand in which circumstances nonrandomized studies are most likely to give reliable answers
and which design and analytical features are most important for generating robust estimates of treatment effects.
Conclusion
While most HTA bodies have a strong preference for evidence on treatment effects to be derived from RCTs, they
are increasingly being asked to make reimbursement and/or pricing decisions based on nonrandomized studies.
These studies are at higher risk of bias than RCTs meaning estimates of clinical effectiveness are often highly
uncertain. When RCT evidence is insufficient for decision making, rigorous and extensive processes should be
followed to ensure that evidence derived from nonrandomized studies is of high quality and those conducting such
studies adhere to best practices, including the use of high-quality data, addressing bias and confounding using
appropriate methods and transparency in study design, conduct, analysis and reporting. Even with high-quality
research, HTA bodies should recognize the uncertainty inherent in nonrandomized studies and establish robust
mechanisms to mitigate the risks for population health thereby imposed.
Executive summary
• There is increasing interest in estimating treatment effects from nonrandomized studies for health technology
assessment (HTA), but limited guidance from HTA bodies on expectations around evidence quality and study
conduct.
• We developed several recommendations aimed at both evidence developers and HTA bodies to improve the
quality and value of nonrandomized studies.
• These recommendations were informed by a pragmatic literature review and a workshop involving 16 HTA
experts from eight European countries.
• To ensure HTA processes remain rigorous and robust, HTA bodies should demand clear, extensive and structured
reporting of nonrandomized studies, including an in-depth assessment of the risk of bias.
• In recognition of the additional uncertainty imparted by nonrandomized designs in estimates of treatment
effects, HTA bodies should strengthen early scientific advice and consider using managed entry agreements
that may help mitigate clinical uncertainty if well designed.
• HTA bodies must also ensure that staff are equipped with the requisite skills to critically appraise nonrandomized
studies.
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